{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:15:34Z","timestamp":1792782934501,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hospices Civils de Lyon","id":[{"id":"https:\/\/ror.org\/01502ca60","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Nocardiosis is a rare but serious infection occurring predominantly in immunocompromised patients. The CLSI microdilution antimicrobial susceptibility testing is recommended for all nocardioses. Ready-to-use plates are available (Sensititre\u2122 RAPMYCOI), but antimicrobials of interest (e.g. tedizolid, meropenem) are lacking. At the request of the French nocardiosis reference medical biology laboratory, a plate including meropenem and tedizolid was produced (Sensititre\u2122 FRNOCAR1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      FRNOCAR1 was compared to RAPMYCOI using 133 clinical\n                      <jats:italic>Nocardia<\/jats:italic>\n                      isolates containing predominantly\n                      <jats:italic>N. farcinica<\/jats:italic>\n                      (23.3%),\n                      <jats:italic>N. cyriacigeorgica<\/jats:italic>\n                      (24.8%), and\n                      <jats:italic>N. nova<\/jats:italic>\n                      complex (21.1%). Acceptability was assessed using the FDA criteria (essential\/category agreement; major, and very major error [VME] rates).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All criteria were respected for 6 antimicrobials; for 5, the upper limit of the VME rate exceeded the criteria, despite a point estimate of 0.0%, due to a lack of resistant strains in the collection. For linezolid, the VME rate could not be calculated due to the absence of linezolid-resistant strains. Tedizolid minimal inhibitory concentration (MIC)50\/MIC90 were 2\u20133 dilutions lower than that of linezolid (0.5\/0.5\u00a0\u00b5g\/mL and 2\/4 \u00b5g\/mL, respectively). Imipenem was better than meropenem for\n                      <jats:italic>N. farcinica<\/jats:italic>\n                      ; meropenem MIC was at least 2-dilutions lower than that of imipenem for\n                      <jats:italic>N. gamkensis<\/jats:italic>\n                      (8\/8),\n                      <jats:italic>N. gipuzkoensis<\/jats:italic>\n                      (2\/4), and\n                      <jats:italic>N. wallacei<\/jats:italic>\n                      (4\/6).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For the antimicrobials common to both plates, the FRNOCAR1 demonstrated good agreement compared with RAPMYCOI. FRNOCAR1 includes tedizolid and meropenem, for which MIC could be reported upon justified request, with a comment indicating that these results are pending further validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10096-026-05588-0","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:10:25Z","timestamp":1783170625000},"page":"3103-3115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nocardia antimicrobial susceptibility testing by microdilution: evaluation of ready-to-use plate including tedizolid and meropenem"],"prefix":"10.1007","volume":"45","author":[{"given":"Mateo","family":"Dutarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Genestet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Lina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-1987","authenticated-orcid":false,"given":"Elisabeth","family":"Hodille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"35","key":"5588_CR1","doi-asserted-by":"publisher","first-page":"e0002721","DOI":"10.1128\/cmr.00027-21","volume":"21","author":"RM Traxler","year":"2022","unstructured":"Traxler RM, Bell ME, Lasker B, Headd B, Shieh WJ, McQuiston JR (2022) Updated Review on Nocardia Species: 2006\u20132021. Clin Microbiol Rev 21(35):e0002721. https:\/\/doi.org\/10.1128\/cmr.00027-21","journal-title":"Clin Microbiol Rev"},{"key":"5588_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cmi.2020.12.019","volume":"27","author":"I Margalit","year":"2021","unstructured":"Margalit I, Lebeaux D, Tishler O, Goldberg E, Bishara J, Yahav D et al (2021) How do I manage nocardiosis? Clin Microbiol Infect 27:550\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2020.12.019","journal-title":"Clin Microbiol Infect"},{"key":"5588_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00005792-199807000-00004","volume":"77","author":"DP Kontoyiannis","year":"1998","unstructured":"Kontoyiannis DP, Ruoff K, Hooper DC (1998) Nocardia bacteremia: report of 4 cases and review of the literature. Medicine 77:255","journal-title":"Medicine"},{"key":"5588_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijid.2018.12.010","volume":"81","author":"SR Ott","year":"2019","unstructured":"Ott SR, Meier N, Kolditz M, Bauer TT, Rohde G, Presterl E et al (2019) Pulmonary nocardiosis in Western Europe-Clinical evaluation of 43 patients and population-based estimates of hospitalization rates. Int J Infect Dis 81:140\u2013148. https:\/\/doi.org\/10.1016\/j.ijid.2018.12.010","journal-title":"Int J Infect Dis"},{"issue":"80","key":"5588_CR5","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1093\/cid\/ciae643","volume":"15","author":"ZA Yetmar","year":"2025","unstructured":"Yetmar ZA, Marty PK, Clement J, Miranda C, Wengenack NL, Beam E (2025) State-of-the-Art Review: Modern Approach to Nocardiosis\u2014Diagnosis, Management, and Uncertainties. Clin Infect Dis 15(80):e53-64. https:\/\/doi.org\/10.1093\/cid\/ciae643","journal-title":"Clin Infect Dis"},{"key":"5588_CR6","unstructured":"Clinical and laboratory standards institute (2018) M24 - Susceptibility testing of Mycobacteria, Nocardia spp., and Other aerobic actinomycetes. 3rd Edition"},{"key":"5588_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01537-17","volume":"61","author":"BA Brown-Elliott","year":"2017","unstructured":"Brown-Elliott BA, Wallace RJ (2017) In vitro susceptibility testing of tedizolid against isolates of Nocardia. Antimicrob Agents Chemother 61:e01537-17. https:\/\/doi.org\/10.1128\/AAC.01537-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"14","key":"5588_CR8","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1038\/s41598-024-55916-7","volume":"4","author":"M Toyokawa","year":"2024","unstructured":"Toyokawa M, Ohana N, Tanno D, Imai M, Takano Y, Ohashi K et al (2024) In vitro activity of tedizolid against 43 species of Nocardia species. Sci Rep 4(14):5342. https:\/\/doi.org\/10.1038\/s41598-024-55916-7","journal-title":"Sci Rep"},{"key":"5588_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14174","volume":"26","author":"M Sogbe","year":"2024","unstructured":"Sogbe M, Di Frisco M, Del Pozo JL (2024) Efficacy and safety of long-term use of tedizolid in disseminated nocardiosis after heart transplantation. Transpl Infect Dis 26:e14174. https:\/\/doi.org\/10.1111\/tid.14174","journal-title":"Transpl Infect Dis"},{"key":"5588_CR10","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1093\/jac\/dkad299","volume":"178","author":"S Corcione","year":"2023","unstructured":"Corcione S, Vita D, De Nicol\u00f2 A, Scabini S, Mornese Pinna S, Cusato J et al (2023) Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient. J Antimicrob Chemother 178:3003\u20133004. https:\/\/doi.org\/10.1093\/jac\/dkad299","journal-title":"J Antimicrob Chemother"},{"key":"5588_CR11","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s10096-021-04186-6","volume":"40","author":"S Soueges","year":"2021","unstructured":"Soueges S, Triffault-Fillit C, Roux S, Labussi\u00e8re-Wallet H, Lebeaux D, Dumitrescu O et al (2021) Long-term use of liposomal nebulized amikacin and tedizolid for the treatment of disseminated nocardiosis after allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis 40:2033\u20136. https:\/\/doi.org\/10.1007\/s10096-021-04186-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"43","key":"5588_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.7399\/fh.11256","volume":"1","author":"V Gim\u00e9nez-Arufe","year":"2019","unstructured":"Gim\u00e9nez-Arufe V, Guti\u00e9rrez-Urb\u00f3n JM, Blanco-Aparicio M, M\u00edguez-Rey E, Mart\u00edn-Herranz MI (2019) Pulmonary nocardiosis treated with tedizolid. Farm Hosp 1(43):208\u2013210. https:\/\/doi.org\/10.7399\/fh.11256","journal-title":"Farm Hosp"},{"key":"5588_CR13","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jiac.2022.03.020","volume":"28","author":"Y Chomei","year":"2022","unstructured":"Chomei Y, Nishimura S, Iwata K (2022) Long-term use of tedizolid for pulmonary nocardiosis. J Infect Chemother 28:1172\u20131176. https:\/\/doi.org\/10.1016\/j.jiac.2022.03.020","journal-title":"J Infect Chemother"},{"key":"5588_CR14","doi-asserted-by":"publisher","first-page":"ofac028","DOI":"10.1093\/ofid\/ofac028","volume":"23","author":"T Morrisette","year":"2022","unstructured":"Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M et al (2022) Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. Open Forum Infect Dis 23:9:ofac028. https:\/\/doi.org\/10.1093\/ofid\/ofac028","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"5588_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01282-23","volume":"17","author":"LG Miller","year":"2023","unstructured":"Miller LG, Flores EA, Launer B, Lee P, Kalkat P, Derrah K et al (2023) Safety and tolerability of tedizolid as oral treatment for bone and joint infections. Microbiol Spectr 17(11):e0128223. https:\/\/doi.org\/10.1128\/spectrum.01282-23","journal-title":"Microbiol Spectr"},{"key":"5588_CR16","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1017\/ash.2024.487","volume":"5","author":"A Greenfield","year":"2025","unstructured":"Greenfield A, Deja E, Lee K, Sastry S, Rittmann B (2025) Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis. Antimicrob Steward Healthc Epidemiol 5:e20. https:\/\/doi.org\/10.1017\/ash.2024.487","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"5588_CR17","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/JCM.00298-16","volume":"54","author":"BA Brown-Elliott","year":"2016","unstructured":"Brown-Elliott BA, Killingley J, Vasireddy S, Bridge L, Wallace RJ (2016) In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest. J Clin Microbiol 54:1586\u20131592. https:\/\/doi.org\/10.1128\/JCM.00298-16","journal-title":"J Clin Microbiol"},{"key":"5588_CR18","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/jac\/dkaf312","volume":"380","author":"J Yang","year":"2025","unstructured":"Yang J, Jiang T, Zhang M, Xue J, Shi D (2025) Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones. J Antimicrob Chemother 380:2862\u20132872. https:\/\/doi.org\/10.1093\/jac\/dkaf312","journal-title":"J Antimicrob Chemother"},{"key":"5588_CR19","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.transproceed.2025.07.020","volume":"57","author":"G Sailaiajimu","year":"2025","unstructured":"Sailaiajimu G, Lu C (2025) Cerebral Nocardia Infections Following Lung Abscesses in a Kidney Transplant Recipient: A Case Report and Literature Review. Transpl Proc 57:1338\u20131343. https:\/\/doi.org\/10.1016\/j.transproceed.2025.07.020","journal-title":"Transpl Proc"},{"key":"5588_CR20","doi-asserted-by":"publisher","first-page":"e39019","DOI":"10.1097\/MD.0000000000039019","volume":"19","author":"K Xue","year":"2024","unstructured":"Xue K, Zhang A, Liu S, Chen D (2024) Multiple brain abscesses caused by Nocardia farcinica infection after hand injury: A case report and literature review. Med (Baltim) 19:103:e39019. https:\/\/doi.org\/10.1097\/MD.0000000000039019","journal-title":"Med (Baltim)"},{"key":"5588_CR21","doi-asserted-by":"publisher","first-page":"952","DOI":"10.4103\/ajns.AJNS_66_19","volume":"14","author":"S Joshua","year":"2019","unstructured":"Joshua S, Babu R, Warrier A, Panikar D (2019) Nocardia araoensis Causing Brain Abscess. Asian J Neurosurg 14:952\u2013956. https:\/\/doi.org\/10.4103\/ajns.AJNS_66_19","journal-title":"Asian J Neurosurg"},{"key":"5588_CR22","doi-asserted-by":"publisher","unstructured":"Hodille E, Prudhomme C, Dumitrescu O, Benito Y, Dauwalder O, Lina G (2023) Rapid, Easy, and Reliable Identification of Nocardia sp. by MALDI-TOF Mass Spectrometry, VITEK\u00ae-MS IVD V3.2 Database, Using Direct Deposit. Int J Mol Sci 13(24):5469. https:\/\/doi.org\/10.3390\/ijms24065469","DOI":"10.3390\/ijms24065469"},{"key":"5588_CR23","unstructured":"Clinical and laboratory standards institute (2018) M62 - Performance Standards for Susceptibility testing of Mycobacetria, Nocardia spp., and other aerobic actinomycetes. 1St Edition"},{"key":"5588_CR24","unstructured":"Amara M, Barraud O, Cadenet J, Cattoir V, Dortet L, Dupieux C et al (2025) Recommandations 2025 V.1.1 Juillet. Comit\u00e9 de l\u2019antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie [Internet] 2025; https:\/\/www.sfm-microbiologie.org\/boutique\/_comite-de-lantibiogramme-de-la-sfm-ca-sfm-v1-1-juilet-2025\/"},{"key":"5588_CR25","unstructured":"Health CforD and R. Antimicrobial Susceptibility Test (AST) Systems - Class II Special Controls Guidance for Industry and FDA. FDA [Internet] 2023 17 [cited 2023 19]\u00a0https:\/\/www.fda.gov\/medical-devices\/guidance-documents-medical-devices-and-radiation-emitting-products\/antimicrobial-susceptibility-test-ast-systems-class-ii-special-controls-guidance-industry-and-fda"},{"issue":"10","key":"5588_CR26","doi-asserted-by":"publisher","first-page":"e0156021","DOI":"10.1128\/spectrum.01560-21","volume":"27","author":"H Wang","year":"2022","unstructured":"Wang H, Zhu Y, Cui Q, Wu W, Li G, Chen D et al (2022) Epidemiology and Antimicrobial Resistance Profiles of the Nocardia Species in China, 2009 to 2021. Microbiol Spectr 27(10):e0156021. https:\/\/doi.org\/10.1128\/spectrum.01560-21","journal-title":"Microbiol Spectr"},{"key":"5588_CR27","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3390\/antibiotics11101438","volume":"19","author":"S-F Kuo","year":"2022","unstructured":"Kuo S-F, Chen F-J, Lan I-C, Chien C-C, Lee C-H (2022) Epidemiology of Nocardia Species at a Tertiary Hospital in Southern Taiwan, 2012 to 2020: MLSA Phylogeny and Antimicrobial Susceptibility. Antibiot (Basel) 19:11:1438. https:\/\/doi.org\/10.3390\/antibiotics11101438","journal-title":"Antibiot (Basel)"},{"issue":"72","key":"5588_CR28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/jac\/dkw489","volume":"1","author":"S Valdezate","year":"2017","unstructured":"Valdezate S, Garrido N, Carrasco G, Medina-Pascual MJ, Villal\u00f3n P, Navarro AM et al (2017) Epidemiology and susceptibility to antimicrobial agents of the main Nocardia species in Spain. J Antimicrob Chemother 1(72):754\u2013761. https:\/\/doi.org\/10.1093\/jac\/dkw489","journal-title":"J Antimicrob Chemother"},{"key":"5588_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cmi.2018.06.013","volume":"25","author":"D Lebeaux","year":"2019","unstructured":"Lebeaux D, Bergeron E, Berthet J, Djadi-Prat J, Mouni\u00e9e D, Boiron P et al (2019) Antibiotic susceptibility testing and species identification of Nocardia isolates: a retrospective analysis of data from a French expert laboratory, 2010\u20132015. Clin Microbiol Infect 25:489\u2013495. https:\/\/doi.org\/10.1016\/j.cmi.2018.06.013","journal-title":"Clin Microbiol Infect"},{"key":"5588_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/antibiotics10070755","volume":"22","author":"A Rodr\u00edguez-Gasc\u00f3n","year":"2021","unstructured":"Rodr\u00edguez-Gasc\u00f3n A, Aguirre-Qui\u00f1onero A, Aspiazu MAS, Canut-Blasco A (2021) Pharmacokinetic\/Pharmacodynamic Analysis of Tedizolid Phosphate Compared to Linezolid for the Treatment of Infections Caused by Gram-Positive Bacteria. Antibiot (Basel) 22:10:755. https:\/\/doi.org\/10.3390\/antibiotics10070755","journal-title":"Antibiot (Basel)"},{"key":"5588_CR31","doi-asserted-by":"publisher","unstructured":"Hershko Y, Levytskyi K, Rannon E, Assous MV, Ken-Dror S, Amit S, et al. Phenotypic and genotypic analysis of antimicrobial resistance in Nocardia species. J Antimicrob Chemother 2023 5;78:2306\u201314. https:\/\/doi.org\/10.1093\/jac\/dkad236","DOI":"10.1093\/jac\/dkad236"},{"key":"5588_CR32","doi-asserted-by":"publisher","unstructured":"Fu K, White K, Ramaniuk A, Kollu V, Urbine D. Manifestations and management of trimethoprim\/sulfamethoxazole-resistant Nocardia otitidiscaviarum Infection. Emerg Infect Dis 2023;29:1266\u20137. https:\/\/doi.org\/10.3201\/eid2906.221854","DOI":"10.3201\/eid2906.221854"},{"key":"5588_CR33","doi-asserted-by":"publisher","unstructured":"Meena DS, Kumar D, Bohra GK, Midha N, Garg MK. Clinical characteristics and treatment outcome of central nervous system nocardiosis: a systematic review of reported cases. Med Princ Pract 2022 14;31:333\u201341. https:\/\/doi.org\/10.1159\/000525509","DOI":"10.1159\/000525509"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05588-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05588-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05588-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:02:35Z","timestamp":1792281755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05588-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5588"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05588-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}